BXL628, a novel vitamin D3 analog arrests prostate growth in patients with benign prostatic hyperplasia: a randomized clinical trial.

@article{Colli2006BXL628AN,
  title={BXL628, a novel vitamin D3 analog arrests prostate growth in patients with benign prostatic hyperplasia: a randomized clinical trial.},
  author={Enrico Colli and Patrizio Rigatti and Francesco Montorsi and Walter Artibani and Stefano Petta and Nicola Mondaini and Roberto Mario Scarpa and Paolo Usai and Lorenza Olivieri and Mario Maggi},
  journal={European urology},
  year={2006},
  volume={49 1},
  pages={82-6}
}
OBJECTIVE To evaluate the effect of BXL628, a vitamin D3 analog, on prostate volume in patients with benign prostatic hyperplasia (BPH). METHODS We conducted a phase II, double blind, randomized, placebo controlled, clinical study. Patients eligible were aged>or=50 years, had a diagnosis of BPH and a prostate volume>or=40 ml. Eligible patients were randomized and given either BXL628 150 mcg daily or placebo for 12 weeks. All randomized patients underwent at baseline and at the end of study… CONTINUE READING